Biogen Inc. $BIIB Shares Bought by Caprock Group LLC

Caprock Group LLC raised its holdings in Biogen Inc. (NASDAQ:BIIB) by 318.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,453 shares of the biotechnology company’s stock after acquiring an additional 17,842 shares during the period. Caprock Group LLC’s holdings in Biogen were worth $4,127,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. First Horizon Corp acquired a new stake in Biogen in the 4th quarter valued at about $30,000. GoalVest Advisory LLC acquired a new stake in Biogen in the 4th quarter valued at about $35,000. Accredited Wealth Management LLC grew its stake in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. Elevation Wealth Partners LLC increased its holdings in shares of Biogen by 412.8% during the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock worth $35,000 after buying an additional 161 shares during the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.18% of the company’s stock.

Biogen Stock Down 1.2%

Biogen stock opened at $187.88 on Friday. Biogen Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The firm has a 50 day moving average price of $185.37 and a 200 day moving average price of $174.82. The company has a market capitalization of $27.57 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.54 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter last year, the firm earned $3.44 EPS. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts expect that Biogen Inc. will post 15.75 earnings per share for the current year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a “slew of pipeline catalysts” over the next 12–15 months that could materially boost revenue and valuation. Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Neutral Sentiment: Several analysts issued mixed takes — some raising targets but keeping neutral ratings, which suggests upside is acknowledged but not consensus conviction. This readjusts expectations without flipping broad buy/sell positioning. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB)…
• Neutral Sentiment: JPMorgan raised its price target to $185 but kept a Neutral rating — marginally higher valuation support but still limited upside per their view. MarketScreener: JPMorgan adjusts price target on Biogen to $185
• Neutral Sentiment: Rothschild & Co Redburn raised its target to $180 but kept a Neutral rating — another example of price‑target lift without a buy endorsement. MarketScreener: Rothschild & Co Redburn adjusts Biogen price target to $180
• Neutral Sentiment: Jim Cramer noted he’s “reopening the file” on Biogen after recent coverage and upgrades — a media boost that can support short‑term interest but isn’t an analyst endorsement. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Negative Sentiment: Wolfe Research trimmed its Q1 2026 EPS estimate (from $2.79 to $2.64) even as it nudged FY‑2027 estimates higher — the near‑term cut can pressure the stock ahead of earnings.
• Negative Sentiment: HSBC reiterated a Reduce rating and uses a $150 target — a markedly lower anchor than UBS and others, which can prompt selling by investors who follow conservative sell‑side views. What is HSBC’s Estimate for Biogen Q1 Earnings?
• Neutral Sentiment: Barclays reaffirmed its Hold rating — another stabilizing but non‑bullish stance. Barclays Reaffirms Their Hold Rating on Biogen (BIIB)

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HSBC raised their price target on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. BMO Capital Markets upped their price objective on Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a report on Friday, February 6th. JPMorgan Chase & Co. upped their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday. Mizuho upped their price objective on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Fourteen investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $211.31.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.